Cytek Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Cytek Biosciences has a total shareholder equity of $389.1M and total debt of $3.3M, which brings its debt-to-equity ratio to 0.8%. Its total assets and total liabilities are $483.7M and $94.6M respectively.
Key information
0.8%
Debt to equity ratio
US$3.26m
Debt
| Interest coverage ratio | n/a |
| Cash | US$277.21m |
| Equity | US$389.12m |
| Total liabilities | US$94.60m |
| Total assets | US$483.73m |
Recent financial health updates
Recent updates
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story
Sep 13
An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued
Aug 09Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Jul 12Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
Jun 04Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Mar 20Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals
Mar 08Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
Jul 27Checking In On Cytek Biosciences
Mar 23Financial Position Analysis
Short Term Liabilities: CTKB's short term assets ($384.1M) exceed its short term liabilities ($52.4M).
Long Term Liabilities: CTKB's short term assets ($384.1M) exceed its long term liabilities ($42.2M).
Debt to Equity History and Analysis
Debt Level: CTKB has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CTKB's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CTKB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CTKB is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 14.9% per year.